

HCV2020


MONTREAL | JULY 6–9, 2020

27th International Symposium on Hepatitis C Virus and Related Viruses

Centre Mont Royal, Montreal, QC, Canada

www.hcv2020.com

MEETING PROSPECTUS



Meeting Chairs



Naglaa H. Shoukry, BPharm, PhD,
Professor of Medicine, University of Montreal
and University of Montreal Hospital Research Center

Director, Canadian Network on Hepatitis C (CanHepC)

Dr. Shoukry obtained her Pharmacy degree from Cairo University (1991) and Ph.D. in Immunology from McGill University (2000). Her postdoctoral research has established the essential and complementary roles of CD8 and CD4 T lymphocytes in resolution and protection from HCV infection. Since joining the CRCHUM in 2005, she has established a translational research program focused on studying immunity to HCV in people who inject drugs. Recently, her research has expanded to studying immunological mechanisms of liver fibrosis progression and development of liver cancer. She has published over 75 articles in high impact journals related to liver immunology and has received multiple awards from the American Liver Foundation, the Canadian Institutes of Health Research (CIHR) and Fonds de recherche du Québec – Santé (FRQS). Since 2015 she has been the Director of the Canadian Network on Hepatitis C (CanHepC), a federally funded network with over 100 investigators, trainees and knowledge users working towards establishing a pipeline from research to implementation and to improve the lives of Canadians living with hepatitis C.



Jordan Feld, MPH, MD
Associate Professor of Medicine, University of Toronto, Ontario, Canada

Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.



Daniel Lamarre, PhD
Professor, Department of Pathology, Case Western Reserve University, Cleveland, OH, USA

Dr. Lamarre has completed his doctoral studies in biochemistry at the Université de Sherbrooke (Canada) and postdoctoral training in immunology at IRCM (Montreal) and Genentech (San Francisco). He then joined Boehringer Ingelheim R&D Canada, where he contributed to research programs in the areas of HIV and HCV infectious diseases. As the HCV therapeutic head, he established a leading position world-wide with the discovery of BILN 2061 (ciluprevir), the first-in-class antiprotease compound ever tested in human for the treatment of HCV infection. Over the last 25 years, he made significant contributions in deciphering molecular aspects of virus-host interactions and identifying regulators of the intrinsic innate immune response through system biology approaches. In 2003, he began his academic career at the Université de Montréal as full professor and co-founder of IRIC - one of the first System Biology Research Institute in Canada. Recently, he joined the Center for Systems Immunology (CSI) at Case Western Reserve University where he focuses his research on engineered T memory stem cells and antigen targeted CAR-T therapy for virus infection and cancer diseases.

LOCAL ORGANIZING


Mohamed S. Abdel-Hakeem, PhD, University of Pennsylvania, Philadelphia, USA
Lisa Barrett, MD, PhD, Dalhousie University, Halifax, NS
Laurent Chatel-Chaix, PhD, Institut Armand Frappier, Laval, QC
Angela Crawley, PhD, Ottawa Hospital Research Institute, Ottawa, ON
Mel Krajden, MD, University of British Columbia, Vancouver, BC
Sonya MacParland, PhD, University of Toronto, Toronto, ON
Valérie Martel-Laferrrière, MD, MSc, CRCHUM, Montreal, QC
John Pezacki, PhD, University of Ottawa, Ottawa, ON
Rodney Russell, PhD, Memorial University, St-Johns. NL
Selena Sagan, PhD, McGill University, Montreal, QC
Lorne Tyrrell, MD, PhD, University of Alberta, Edmonton, AB
Joyce Wilson, PhD, University of Saskatchewan, Saskatoon, SK

INTERNATIONAL ORGANIZING COMMITTEE (IOC)

Barbara Rehermann (Chair), National Institutes of Health, USA
Thomas Baumert, University of Strasbourg, France
Michael Beard, University of Adelaide, Australia
Andrea Cox, Johns Hopkins School of Medicine, USA
Heidi Drummer, Burnet Institute, Australia
Mark Harris, University of Leeds, UK
Georg Lauer, Massachusetts General Hospital, Harvard Medical School, USA
Brett Lindenbach, Yale University School of Medicine, USA
Jane MacKeating, University of Oxford, UK
Philip Meuleman, Ghent University, Belgium
Naglaa Shoukry, University de Montréal, Canada
Eui-Cheol Shin, Korea Advanced Institute of Technology, Seoul, Korea
Nigel Stevenson, Trinity College, Dublin, Ireland
Robert Thimme, University Hospital Freiburg, Germany
Takaji Wakita, National Institute of Infectious Diseases, Japan


INTERNATIONAL ADVISORY COMMITTEE (IAC)

Sergio Abrignani, Istituto Nazionale Genetica Molecolare, Italy
Ralf Bartenschlager, University of Heidelberg, Germany
Raymond Chung, Massachusetts General Hospital, Harvard Medical School, USA
Michael Houghton, University of Alberta, Canada
Daniel Lamarre, Case Western Reserve University, USA
Stanley Lemon, University of North Carolina, USA
Jake Liang, National Institutes of Health, USA
Yoshii Matsuura, Osaka University, Japan
John McLauchlan, University of Glasgow, UK
Tatsuo Miyamura, National Institute of Health and Nutrition, Tokyo, Japan
Jean-Michel Pawlotsky, Henri Mondor University Hospital, France
Steve Polyak, University of Washington, USA
Charles Rice, Rockefeller University, USA
Lorne Tyrrell, University of Alberta, Canada
Chris Walker, Nationwide Children's Hospital, USA



Background


The **International Symposium on Hepatitis C Virus and Related Viruses** has been a recurring annual conference since 1994. It has become the main forum for basic science investigators working on hepatitis C virus (HCV) and related viruses. Over the past 26 years, this conference has been instrumental in developing and advancing major discoveries in the HCV field including the understanding of the virus life cycle and development of in vitro replication systems and animal models. This meeting has fostered the discovery and development of direct acting antivirals (DAA) that have revolutionized the treatment of HCV infection. Understanding the immune response and pathogenesis of chronic HCV infection presented at this meeting are now the basis for ongoing vaccine development and preclinical trials. Despite this progress, basic research on HCV infection remains at the forefront to drive HCV elimination efforts and reduce the morbidity and mortality of the disease. Research into vaccine development, HCV pathogenesis and liver cancer following DAA treatment, novel diagnostics and sequencing approaches to track the evolution and transmission of HCV in at-risk populations are only some of the key remaining research questions.



Meeting Objective


The HCV2020 meeting will focus on the main objective of HCV elimination by bringing together Basic and Clinical investigators to discuss the remaining challenges in the HCV field and novel approaches to tackle them towards this aim. The symposium will bring together keynote lectures from outstanding senior investigators and rising stars in virology, immunology and liver disease. In addition, high quality oral and poster presentations will be selected from submitted abstracts.


Conference Venue

 **Centre Mont Royal, Montreal, QC, Canada**

Anticipated number of delegates

400 Attendees





Program at a glance

Time	Monday	Tuesday	Wednesday	Thursday	
	July 6, 2020	July 7, 2020	July 8, 2020	July 9, 2020	
8:30 - 9:00	Industry Sponsored Symposium 1	Session 3: Viral Life Cycle 1	Session 7: Liver Inflammation, Viral Pathogenesis and Carcinogenesis	Session 10: Antivirals: Challenges and New Frontiers	
9:00 - 9:30					
9:30 - 10:00					
10:00 - 10:30	Coffee Break	Coffee Break		Coffee Break	
10:30 - 11:00	Industry Sponsored Symposium 2	Session 4: Viral Life Cycle 2	Coffee Break	Session 11: Vaccines	
11:00 - 11:30			Session 8: Late Breakers		
11:30 - 12:00					
12:00 - 12:30	Lunch	Lunch	Lunch	Lunch	
12:30 - 13:00					
13:00 - 13:30					
13:30 - 14:00	Opening Ceremony	Session 5: Adaptive Immunity	Session 9: Animal Models, organoids and replication systems	Session 11: Vaccines (Continued)	
14:00 - 14:30	Session 1: Tools for HCV Elimination: Diagnostics, sequencing and beyond				Flash Posters
14:30 - 15:00					
15:00 - 15:30			Coffee Break	Coffee Break	
15:30 - 16:00	Coffee Break	Coffee Break	Poster Session 2	Closing Lecture	
16:00 - 16:30	Session 2: Innate Immunity/ Virus-Host Interaction	Session 6: Global Challenges of HCV elimination		HCV-2021 Presentation	
16:30 - 17:00				Closing Remarks	
17:00 - 17:30					
17:30 - 18:00		Poster Session 1			
18:00 - 18:30					
18:30 - 19:00	Welcome Reception			Gala Dinner	
19:00 - 19:30					
19:30 - 20:00					
20:00 - 20:30					

Sponsorship Levels

Level	Amount (USD)	Recognition
Diamond	> \$100,000	<ul style="list-style-type: none">• 100% customized package
Platinum	\$75,000 – \$99,999	<ul style="list-style-type: none">• Four free registrations and Gala tickets• Full page advertisement in the Abstract Book• Logo on event website, acknowledgment slide, meeting program and all promotional materials• Special recognition and standing banner at the meeting• An exhibition table/booth for the whole conference
Gold	50,000 – 74,999	<ul style="list-style-type: none">• Two free registrations and Gala tickets• Logo on event website, acknowledgment slide, meeting program and all promotional materials• An exhibition table/booth for the whole conference
Silver	\$25,000 – 49,999	<ul style="list-style-type: none">• Two free registrations• Logo on event website, acknowledgment slide, meeting program and all promotional materials
Bronze	\$5,000 – \$24,999	<ul style="list-style-type: none">• One free registration• Logo on event website, acknowledgment slide and meeting program

If there isn't a package that suits your organization's needs, we invite you to connect with us to discuss other opportunities.

Additional Opportunities

- Industry sponsored premeeting symposia and lunch symposia
- Delegate Lounge
- Transportation
- The Gala Dinner
- Coffee Breaks
- HCV 2020 Conference App
- The Poster Gallery
- The Welcome Reception
- The Faculty Lounge & Speaker Ready Room
- Reusable water bottles with your logo
- Electronic abstract book on USB key with your logo
- Abstract book advertisement (cost to be determined)
- Travel award support for trainees and young investigators (\$1000 (USD)/award)

Benefits of being part of HCV2020

- 1 Interaction and Networking with the international leaders in the field of HCV
- 2 First-hand opportunity to learn about recent developments in the field and novel technologies guiding HCV elimination efforts
- 3 Promotion of your product and brand name

Contact

HCV2020 Secretariat
c/o Dr. Naglaa Shoukry
Centre de Recherche du CHUM
Tour Viger, Local R09.414
900 rue St-Denis
Montréal, QC H2X 0A9
CANADA

✉ naglaa.shoukry@umontreal.ca

🌐 www.hcv2020.com

🐦 [@HCV2020Montreal](https://twitter.com/HCV2020Montreal)



HCV2020
MONTRÉAL | JULY 6–9, 2020

27th International Symposium on Hepatitis C Virus and Related Viruses